Outcomes in COVID-19 brexanolone studies

0 0.5 1 1.5+ All studies -14% 1 28 Improvement, Studies, Patients Relative Risk Mortality -14% 1 28 RCTs -14% 1 28 Late -14% 1 28 Brexanolone for COVID-19 c19early.org November 2025 Favorsbrexanolone Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Brown (DB RCT) -14% 1.14 [0.57-2.29] death 8/14 7/14 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Late treatment -14% 1.14 [0.57-2.29] 8/14 7/14 14% higher risk All studies -14% 1.14 [0.57-2.29] 8/14 7/14 14% higher risk 1 brexanolone COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Effect extraction pre-specified(most serious outcome) Favors brexanolone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Brown (DB RCT) -14% 1.14 [0.57-2.29] 8/14 7/14 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Late treatment -14% 1.14 [0.57-2.29] 8/14 7/14 14% higher risk All studies -14% 1.14 [0.57-2.29] 8/14 7/14 14% higher risk 1 brexanolone COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Favors brexanolone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Brown (DB RCT) -14% 1.14 [0.57-2.29] death 8/14 7/14 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Late treatment -14% 1.14 [0.57-2.29] 8/14 7/14 14% higher risk All studies -14% 1.14 [0.57-2.29] 8/14 7/14 14% higher risk 1 brexanolone COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Effect extraction pre-specified(most serious outcome) Favors brexanolone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Brown (DB RCT) -14% 1.14 [0.57-2.29] death 8/14 7/14 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Late treatment -14% 1.14 [0.57-2.29] 8/14 7/14 14% higher risk All studies -14% 1.14 [0.57-2.29] 8/14 7/14 14% higher risk 1 brexanolone COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Effect extraction pre-specified(most serious outcome) Favors brexanolone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Brown (DB RCT) -14% 1.14 [0.57-2.29] 8/14 7/14 Ventilated patients Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Late treatment -14% 1.14 [0.57-2.29] 8/14 7/14 14% higher risk All studies -14% 1.14 [0.57-2.29] 8/14 7/14 14% higher risk 1 brexanolone COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.72 Favors brexanolone Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Brown (DB RCT) -14% 1.14 [0.57-2.29] death 8/14 7/14 Ventilated patients Improvement, RR [CI] Treatment Control Brown (DB RCT) -33% 1.33 [0.63-2.84] death 8/14 6/14 Ventilated patients Brown (DB RCT) 0% 1.00 [0.63-1.60] progression 10/14 10/14 Ventilated patients Brexanolone COVID-19 outcomes c19early.org November 2025 Favors brexanolone Favors control